Therapy of viral hepatitis

Area of Science:

• Hepatology and Viral Gastroenterology
• Infectious Diseases and Virology
• Pharmacology and Therapeutics

Background:

• Viral hepatitis is a leading global cause of jaundice, cirrhosis, and hepatocellular carcinoma.
• Current therapies for viral hepatitis, particularly alpha-interferon, are often expensive, poorly tolerated, and have limited effectiveness.
• There is a critical need for more effective treatments for both acute and chronic viral hepatitis.

Purpose of the Study:

• To review the current landscape of viral hepatitis therapy.
• To evaluate the efficacy and limitations of existing treatments like alpha-interferon.
• To explore promising new antiviral agents and combination therapies for hepatitis B and C.

Main Methods:

• Review of existing literature on viral hepatitis treatment.
• Analysis of clinical trial data for alpha-interferon, lamivudine, and other nucleoside analogues.
• Evaluation of treatment outcomes including viral clearance, histological improvement, and patient relapse rates.

Main Results:

• Alpha-interferon yields modest sustained clearance rates for hepatitis B virus (HBV) and hepatitis C virus (HCV).
• Lamivudine demonstrates potent inhibition of HBV DNA and improves liver histology but is associated with relapse and resistance.
• Sustained response to alpha-interferon in chronic hepatitis C is associated with improved histology and potential 'cure'.

Conclusions:

• Better therapies are urgently needed for chronic hepatitis B and C.
• Oral nucleoside analogues like lamivudine offer new avenues, but long-term efficacy and resistance are concerns.
• Combination therapies involving lamivudine, interferon, and other antivirals represent a promising future direction.